REG - Belluscura PLC - Result of General Meeting

BelluscuraAnnouncement

27/08/2024 14:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240827:nRSa8597Ba&default-theme=true

RNS Number : 8597B  Belluscura PLC  27 August 2024

27 August 2024

 

Belluscura plc

("Belluscura" or the "Company")

 

Result of General Meeting

 

Belluscura plc (AIM: BELL), a leading medical device developer focused on
lightweight and portable oxygen enrichment technology, announces that at the
Annual General Meeting held earlier today, all resolutions proposed were duly
approved by shareholders:

 

                                                                                 Total votes for  % of shares voted   Total votes against  % of shares voted   Total votes  Votes withheld
 Ordinary resolutions
 Resolution 1: To receive and adopt the report of the directors and the audited  91,444,802       99.94               55,722               0.06                91,500,524   -
 accounts of the Company for the period ended 31 December 2023
 Resolution 2: To re-elect Simon Neicheril as a director of the Company          91,426,718       99.94               54,753               0.06                91,481,471   19,053
 Resolution 3: To re-elect Robert Fary as a director of the Company              91,426,718       99.94               54,753               0.06                91,481,471   19,053
 Resolution 4: To re-elect Paul Tuson as a director of the Company               91,426,574       99.94               54,897               0.06                91,481,471   19,053
 Resolution 5: To re-appoint Gerald Edelman LLP as auditor to the Company        91,456,503       99.95               43,877               0.05                91,500,380   144
 Resolution 6: To authorise the directors to determine the remuneration of the   91,442,594       99.96               38,877               0.04                91,481,471   19,053
 auditors
 Resolution 7: To grant the directors authority to allot shares pursuant to      91,439,344       99.93               61,180               0.07                91,500,524   -
 Section 551 of the Companies Act 2006 and grant rights to subscribe for, or
 convert any security into, shares
 Special resolutions
 Resolution 8: To dis-apply pre-emption rights pursuant to Section 570 of the    86,818,255       94.90               4,663,216            5.10                91,481,471   19,053
 Companies Act 2006
 Resolution 9: To authorise the directors to make market purchases               86,896,258       94.97               4,604,266            5.03                91,500,524   -

 

 

For further information please contact:

                                              Tel: +44 (0)20 3128 8100

 Belluscura plc
 Adam Reynolds, Chairman

 Robert Rauker, Chief Executive Officer

 Simon Neicheril, Chief Financial Officer

 SPARK Advisory Partners Limited              Tel: +44 (0)20 3368 3550

 (Nominated Adviser)
 Neil Baldwin / Jade Bayat

 Dowgate Capital Limited                      Tel: +44 (0)20 3903 7715

 (Broker)
 James Serjeant / Russell Cook

 MHP Group                                    Tel: +44 (0)20 3128 8100

 (Financial PR & Investor Relations)
 Katie Hunt / Matthew Taylor                   belluscura@mhpgroup.com

 

 

About Belluscura plc (https://belluscura.com/
(https://protect.checkpoint.com/v2/___https:/belluscura.com/___.bXQtcHJvZC1jcC1ldXcyLTE6bmV4dDE1OmM6bzo0NDFjZTEwZTIyNjY4NjYyODQzOGE3NDY2ZTQ1ZjIyYjo2OjQzODY6NWU4MzI1ZmMzYWNlOTUyN2RlNDQ0ZTc0NmZlZWJhYmRlODJjNjBkYzBkODNhZTdkY2UyNTNkOWEwNGE0NWI0YTpwOkY6Tg)
)

 

Belluscura is a UK medical device company focused on developing oxygen
enrichment technology spanning broad industries and therapies. Our innovative
oxygen technologies are designed with a global purpose: to create improved
health and economic outcomes for the patients, healthcare providers and
insurance organisations.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMEADPXAFKLEFA